Day: January 7, 2026

Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through additional FDA Humanitarian Use and Breakthrough Device Designations DENVER, Jan. 07, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its key milestones...

Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense® product line and away from Re-Tain® on December 24, 2025. The Company will also discuss its unaudited topline sales results for the fourth quarter and full year ended December 31, 2025, which will be announced after the market closes on Thursday, January 8, 2026. Conference Calls:The Company is planning to host a conference call on Friday, January 9, 2026...

Beyond line-of-sight V2X technology protects vulnerable road users in connected and autonomous mobility Ness Ziona, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, today announced that its majority-owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), will participate in CES 2026 in Las Vegas and will showcase its commercially-ready vehicle-to-everything (“V2X”) collision prevention technology. By leveraging existing cellular infrastructure, Eye-Net’s proprietary V2X collision prevention technology enables real-time communication between vehicles and vulnerable road users, including pedestrians and cyclists. Eye-Net’s innovative approach to delivering early alerts about cross collision addresses a fundamental...

AUSTIN, Texas and DES MOINES, Iowa, Jan. 07, 2026 (GLOBE NEWSWIRE) — Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a partnership with North American Company for Life and Health Insurance®, introducing a proprietary Accumulation Indexed Universal Life product (IUL) to Ethos’ digital life insurance platform. North American will be a new provider for the Ethos IUL product suite, providing eligible consumers with life insurance coverage up to $2 million.  Ethos and North American’s Accumulation IUL brings strong performance, differentiated benefits, and a faster, simpler process for agents and consumers alike. This new IUL can offer an instant-decision with no medical exams1. Once approved, consumers can secure meaningful coverage in minutes, without medical...

GAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST. The audio link for Emergent’s session may be accessed here and will be live for up to 30 days. The Company’s slides will be made available at the time of the presentation on the Investors section of the Emergent website. About Emergent BioSolutionsAt Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies....

GREENWICH, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, announced that it has renewed its long-standing commitment as the official transportation partner of the Susan G. Komen® 3-Day fundraising walks through March 2029.  “The 3-Day fundraising walks represent hope, strength and progress for those affected by breast cancer,” said Carolyn Roach, chief human resources officer of XPO. “Through our long-term partnership, we are proud to support Susan G. Komen’s mission while giving our employees meaningful ways to make an impact.”  XPO ensures that critical event materials safely reach every city on the 3-Day route by providing complimentary transportation, storage and logistical expertise. Employees also participate in the walks and fundraise in support of...

U.S.-based patients’ expectations for testing are changing, potentially at the expense of evidence-based medicine. Patients, feeling empowered by social media, want greater control over test ordering decisions, and some even dismiss doctors’ expertise, mirroring growing mistrust in authority.Infographic: Patient Expectations for Testing are EvolvingPatients have clear expectations for testing: 93% expect their doctor to order a lab test upon request, with nearly 1 in 5 patients having asked for a lab test based on information learned on social media. Meanwhile, 27% have pursued blood testing by a trusted lab provider out of curiosity, independent of a doctor’s recommendation.Tarrytown, New York, Jan. 07, 2026 (GLOBE NEWSWIRE) —93% of patients expect their doctor to order a test upon request 17% have requested a lab...